trending Market Intelligence /marketintelligence/en/news-insights/trending/pRZft0iv5Jw-hZ12Suqbdg2 content esgSubNav
In This List

Teva's prophylaxis generic gets sole EMA recommendation in October

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Teva's prophylaxis generic gets sole EMA recommendation in October

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of one generic medicine in October: Teva Pharmaceutical Industries Ltd.'s Tacforius, intended for prophylaxis and treatment of transplant rejection.

Separately, the EU panel recommended Roche Holding AG's Alecensa as a first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. The drug was previously recommended as monotherapy for patients that had already been treated with Pfizer Inc.'s Xalkori, or crizotinib.

Santhera Pharmaceuticals Holding AG requested a reexamination of the CHMP's negative opinion for Raxone, or idebenone, intended to treat Duchenne muscular dystrophy, a rare genetic condition characterized by progressive muscle weakness and degeneration. The EMA panel will re-examine the opinion and issue a final recommendation.

The CHMP did not adopt a negative opinion in its October meeting. Also, no company withdrew its application during the month.